APOE and atherosclerosis: As endothelial dysfunction typically precedes the development and progression of atherosclerosis, we speculate that the observed improvement of endothelial function in Apoe−/− HFD mice by SKA-31 treatment may oppose the functional impairments of CV performance that develop beyond the early stage of atherosclerosis when plaques become more permanent and progressive, rather than directly reduce plaque formation.